Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

Autor: Manuel Pérez-Encinas, Pilar Giraldo, L.F. Casado, Carmen Calle, María-Jesús Peñarrubia, Joaquin Martinez-Lopez, J.L. Steegmann, José-Valentín García-Gutiérrez, Luis Palomera, Isabel Massague, Carmen Burgaleta, Guiomar Bautista, Raquel de Paz, Jose Angel Hernandez-Rivas, Begoña Maestro, Santiago Osorio, María-José Requena, Nuria García-Ormeña

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Cancer Medicine

Chronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic scoring systems) and on early response (such as >10% BCR-ABL/ABL ratio at 3 months of therapy).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbfc8d24502055423622ab87243ef2d4
https://doi.org/10.1002/cam4.440

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the 'Watch and Wait' Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

Autor: J Valentin Garcia-Gutierrez, Isabel Massague, Carmen Burgaleta, Carmen Calle, Manuel Pérez-Encinas, Pilar Cano, Pilar Giraldo, Joaquín Martínez, Juan Luis Steegmann, Maria José Requena, María Jesús Peñarrubia, Santiago Osorio, Guiomar Bautista, Luis Felipe Casado, Raquel de Paz, Jose Angel Hernandez-Rivas, Begoña Maestro

Publikováno v: Blood. 120:3768-3768

Abstract 3768 Introduction: Tyrosine kinase inhibitors (TKIs) have dramatically changed chronic myeloid leukemia prognostic. The European Leukemia Net guidelines are widely used for patients treated with TKIs. While strategies for patients with optim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6f071d3e3de83ceaead876984a1abb1
https://doi.org/10.1182/blood.v120.21.3768.3768

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Autor: Manuel Pérez-Encinas, Raquel de Paz, Begoña Maestro, María Jesús Peñarrubia, Isabel Massague, Carmen Calle, Pilar Giraldo, Guiomar Bautista, Juan Luis Steegmann, Santiago Osorio, Luis Palomera, Luis Felipe Casado, Joaquin Martinez-Lopez, Maria José Requena

Publikováno v: Blood. 116:1237-1237

Abstract 1237 Background: The RELMC is a multicentric, 17-hospitals-based cancer registry whose aim is to describe the treatments received by patients with CML, their outcomes, and the variables that influence treatment choices. Aim: To study the res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c196ff5a1f452662b8f626f87ca75d14
https://doi.org/10.1182/blood.v116.21.1237.1237